Jazz Pharmaceuticals completes $820M acquisition of Actio Biosciences, adds ABS-1230 epilepsy candidate
Jazz Pharmaceuticals completed the $820 million acquisition of Actio Biosciences, gaining ABS-1230, a clinical-stage KCNT1-related epilepsy therapy candidate.Key Highlights:Original SEC Filing: Jazz Pharmaceuticals plc [ JAZZ ] - 8-K - Sep. 15, 2026This is an AI-powered summary. It may contain inac…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.